Evidence map›Paper›PMID 35095615›Full record

ArticleFrontiers in psychiatry2021

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D

Jan Kehr, Fu-Hua Wang, Fumio Ichinose, Shimako Yoshitake, Bence Farkas, Béla Kiss, Nika Adham

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Jan KehrPronexus Analytical AB, Bromma, Sweden.
Fu-Hua WangPronexus Analytical AB, Bromma, Sweden.
Fumio IchinosePronexus Analytical AB, Bromma, Sweden.
Shimako YoshitakePronexus Analytical AB, Bromma, Sweden.
Bence FarkasPharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary.
Béla KissPharmacological and Drug Safety Research, Gedeon Richter Plc., Budapest, Hungary.
Nika AdhamAllergan plc, Madison, NJ, United States.
Gedeon Richter (Hungary) · HUKarolinska Institutet · SEAllergan (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The negative and cognitive symptoms of schizophrenia and related disorders may be due to reduced dopaminergic tone in cortical brain areas. Alteration in the function of dopamine (DA) D

Indexed as

cariprazinedopamine D3 receptorhuddlingmicrodialysisschizophrenia

Identifiers

PMID35095615
PMCPMC8789685
OpenAlexW4206510345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.